Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II-Reference-Cited by-同舟云学术

Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II

Author:

Leiter Lawrence A.¹^ORCID,Zamorano José Luis²,Bujas-Bobanovic Maja³,Louie Michael J.⁴,Lecorps Guillaume³,Cannon Christopher P.⁵,Handelsman Yehuda⁶

Affiliation:

1. Li Ka Shing Knowledge Institute and Keenan Research Center for Biomedical Science; St. Michael's Hospital, University of Toronto; Toronto Canada

2. Hospital Universitario Ramon y Cajal, University Alcala de Henares; Madrid Spain

3. Sanofi; Paris France

4. Regeneron Pharmaceuticals; Tarrytown New York

5. Brigham and Women's Hospital; Boston Massachusetts

6. Metabolic Institute of America; Tarzana California

Funder

Sanofi and Regeneron Pharmaceuticals

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

Reference13 articles.

4. 8. Cardiovascular disease and risk management;American Diabetes Association;Diabetes Care,2015

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献